Opyl Limited announced that its clinical trial patient recruitment platform, Opin, has achieved a number of milestones including securing the first in a series of planned global and local strategic alliances with clinical trial aggregators and gateways. The 2-year Memorandum of Understanding (MOU) with CCRM Australia provides Opin with approved supplier access to CCRM industry consortium companies and research organizations in the regenerative medicine industry globally. CCRM Australia and the global CCRM network supports the development and commercialisation of regenerative medicine-based technologies as well as cell and gene therapies. The regenerative medicine (stem cells) field accounts for approximately 10% of Australia's public medical research capacity with more than 30 companies in Australia developing products with a regenerative medicine focus. The key benefits for Opin/Opyl will be in initially accessing the large Australian sub-sector and then accessing the CCRM Global Network in North America and Europe. Opin is now a featured service partner on three state-based clinical trial portals used by biopharma and medtech companies looking to host trials and studies in Australia. Opin.ai matches motivated patients to clinical trials anywhere in the world. The proprietary platform uses artificial intelligence to search and rank a global database on the platform of more than 58,000 open trials that are searching for clinical trial participants. Opin, through its platforms, works with companies to accelerate clinical studies as well as providing patient insights into clinical trial options across diseases and medical conditions. Poor recruitment is frequently cited as one of the core reasons for clinical trial failure 3. More than 80% of clinical trials fail to recruit on time and on budget 4, putting at risk hundreds of millions -- if not billions -- of dollars each year through delays in taking products to market or through complete trial failure as well as delaying vital treatments and medication to patients.